Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an optimal pharmacokinetic/pharmacodynamic target. However, no study has yet evaluated this aspect in the specific scenario of liver transplant patients with documented infections with Gram-negative pathogens.
adult OLT recipients (age ≥ 18 years);
documented Gram-negative infections occurring in the first 90 days after transplantation;
treatment with beta-lactam based-regimens;
signed informed consent.
patients receiving beta-lactam-based regimens for less than 48 hours;
patients with isolation of a Gram-negative resistant to all available beta-lactam classes;
patients on palliative care and/or not resuscitation order.